Insights & Resources

J.P. Morgan's Q1 2025 biopharma and medtech reports reveal larger deals, global growth and financial strategies shaping the life sciences industry.

Discover 10 surprising ways Texas’ rapid growth and advancements are reshaping industries, driving business innovation and creating new opportunities.

Explore ASC 805’s role in bringing clarity to business combinations — from fair value measurements to goodwill and beyond.

J.P. Morgan’s Q3 2024 Biopharma Report highlights robust venture investments, shifting licensing trends and a resurgence in IPO activity.

The Q3 2024 Medtech Report from J.P. Morgan spotlights heightened investments, mergers and public offerings, signaling a positive industry outlook.

Due diligence is a crucial step in any merger and acquisition process. This can be especially challenging for Software-as-a-Service (SaaS) companies.

With an increasing demand for lithium across the energy sector, oilfields may find a common biproduct may hold the key to future growth.

The medical technology, or medtech, industry is poised for a transformative year despite soft IPO activity the first half of 2024. Learn more here.

Facing limited resources and increasingly rapid technology advances, public service organizations must evolve their processes, systems and infrastructure to embrace existing shifts.

PCI DSS sets the standard for payment card security in higher education detailing compliance levels, reporting requirements and strategies to protect data.

Whether preceding an M&A transaction or another executive hire, due diligence identifies any red flags before inking a high-stakes deal.

In a business sale, due diligence is critical to mitigate the risk of unexpected tax issues for buyers and sellers. Find out key components of tax due diligence.